XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
License Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Nov. 22, 2021
Aug. 30, 2021
Dec. 08, 2020
Dec. 31, 2021
Jan. 31, 2021
Dec. 31, 2020
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 21, 2021
Capitalized Contract Cost [Line Items]                      
Royalties accrued on product sales             $ 500,000 $ 500,000 $ 900,000 $ 900,000  
Upfront payment         $ 14,000,000.0            
Total revenue           $ 14,000,000.0 6,179,000 6,202,000 11,532,000 12,069,000  
Amount of certain development, regulatory, and sales milestones payments eligible to receive under license agreement     $ 257,000,000                
Right to terminate the agreement     120 days                
Celgene License Agreement                      
Capitalized Contract Cost [Line Items]                      
Payment of license fees   $ 5,800,000                  
Related party transaction, balloon payment interest rate per annum   4.00%                  
Celgene License Agreement | EOC Pharma (Hong Kong) Limited                      
Capitalized Contract Cost [Line Items]                      
Payment received from license agreement         $ 14,000,000.0            
Celgene License Agreement                      
Capitalized Contract Cost [Line Items]                      
Payments related to milestone             $ 0 $ 0 $ 0 $ 0  
License fees, percentage of previously outstanding payment obligation   50.00%                  
Due to licensor   $ 5,800,000                  
Celgene License Agreement | EOC Pharma (Hong Kong) Limited                      
Capitalized Contract Cost [Line Items]                      
Payments related to milestone       $ 1,000,000              
Due to licensor                     $ 200,000
Sublicense fees, percentage     20.00% 20.00%              
Total revenue $ 1,000,000